This is not a real interview. It probably was written by Biota, or certainly vetted by them. Its a marketing tool used by many companies. This is Biota's attempt at PR. Unfortunatley it raises more questions than answers.
He states that anitvirals are both seasonal and cyclical - but no explanation why Relenza is selling very little seasonally.
There was no clarification on ROW sharing negotiations with DS.
I was a little concerned with the comments that BARDA funding is for biodefence and not for products that are likely to be used under normal commercial terms. What does that mean?
BTA Price at posting:
90.5¢ Sentiment: Hold Disclosure: Held
